Search results
16 mar 2023 · Cardiac sarcoidosis (CS) results from epithelioid cell granulomas infiltrating the myocardium and predisposing to conduction disturbances, ventricular tachyarrhythmias, and heart failure. Manifest CS, however, constitutes only the top of an iceberg as advanced imaging uncovers cardiac involvement 4 to 5 times more commonly than what is ...
18 kwi 2024 · Cardiac sarcoidosis (CS) is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium. Common presentations include high-grade conduction disease, ventricular arrhythmias (VAs), or left ventricular (LV) dysfunction. Accurate diagnosis is challenging because of the diverse and nonspecific presentations.
1 mar 2024 · Cardiac sarcoidosis (CS) refers to granulomatous inflammation that affects the heart in isolation or as part of systemic sarcoidosis. Based on imaging and autopsy findings, CS occurs in approximately 25% of patients with sarcoidosis.
JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis (Tables 2,3). 2. Guidelines from the Heart Rhythm Society (HRS 2014) . 3. Guidelines for diagnosing CS from the Japanese Ministry of Health Welfare 2006 (JMHW) . 4. World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Organ (WASOG) Criteria 1999. ...
The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricular arrhythmias, and heart failure. An estimated 20% to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clinically silent disease).
5 mar 2024 · This topic will discuss the clinical manifestations of cardiac sarcoidosis and provide an overview of how to evaluate patients with suspected cardiac sarcoidosis. Management and prognosis of cardiac sarcoidosis and diagnosis and management of systemic sarcoidosis are discussed separately.
26 lip 2016 · The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricular arrhythmias, and heart failure. An estimated 20% to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clinically silent disease).
